Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Diabetes Reviews
  4. Volume 21, Issue 5
  5. Article
Volume 21, Issue 5
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417

Abstract

Prediabetes increases the risk of type 2 diabetes, metabolic syndrome, chronic renal disease, and cardiovascular disease in a person. In current practice, five alternative definitions of prediabetes are utilized, each based on different HbA1c, fasting glucose, and 2-hour glucose cut points. Prediabetes is a common condition that occurs between normal glycemia and diabetes. It is more common in elderly and obese people. The prevalence of prediabetes and diabetes can be influenced by a variety of individual, family, and societal variables. Additionally, as diabetes is the primary contributor to non-communicable diseases (NCD), it is crucial to identify the key temporal variables for diabetes early diagnosis. In turn, effective prediabetes and diabetes awareness, control, and preventive programs may be created by policymakers and public health professionals worldwide. Popular pathogenic pathways in prediabetes include insulin resistance, inflammation, and sensitivity to insulin. HBA1c, OGTT, and FPG are discussed as the diagnostic criteria in order of frequency. The most commonly researched therapies in the realm of prediabetes are metformin, exercise, and physical activity. Physiological markers including BMI, blood pressure, and waist circumference prompted relatively significant concern. Despite declining trends, the study demonstrates that prediabetes and diabetes are widely prevalent. In order to prevent non-communicable illnesses, the research suggests encouraging healthy lifestyles and regular screenings.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998285294240307052909
2024-04-03
2025-01-18

  • From This Site

    /content/journals/cdr/10.2174/0115733998285294240307052909
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. American Diabetes AssociationClassification and diagnosis of diabetes: Standards of medical care in diabetes-2020.Diabetes Care202043S1S14S3131862745
     [Google Scholar]
  2. TabákA.G. HerderC. RathmannW. BrunnerE.J. KivimäkiM. Prediabetes: A high-risk state for diabetes development.Lancet201237998332279229010.1016/S0140‑6736(12)60283‑922683128
     [Google Scholar]
  3. VasP.R.J. AlbertiK.G. EdmondsM.E. Prediabetes: Moving away from a glucocentric definition.Lancet Diabetes Endocrinol.201751184884910.1016/S2213‑8587(17)30234‑628781065
     [Google Scholar]
  4. WHO, International Diabetes FoundationDefinition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation.GenevaWorld Health Organization2006
     [Google Scholar]
  5. GoldenbergR. PunthakeeZ. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome.Can. J. Diabetes201337S1S8S1110.1016/j.jcjd.2013.01.01124070969
     [Google Scholar]
  6. American Diabetes AssociationClassification and diagnosis of diabetes: Standards of medical care in diabetes-2018.Diabetes Care201841S1S13S2710.2337/dc18‑S00229222373
     [Google Scholar]
  7. Centers for Disease Control and PreventionNational diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States.Atlanta, GAUS Department of Health and Human Services, Centers for Disease Control and Prevention2011
     [Google Scholar]
  8. American Diabetes Association Diagnosis and classification of diabetes mellitus.Diabetes Care2011341S62S69
     [Google Scholar]
  9. Prevention or delay of type 2 diabetes: Standards of Medical Care in Diabetes–2020.Diabetes Care2020431S32S3631862746
     [Google Scholar]
  10. WagnerA. Prediabetes An Emerging Epidemic.Ann Arbor, MIUniversity of Michigan Health System2015110
     [Google Scholar]
  11. MakaroffL.E. The need for international consensus on prediabetes.Lancet Diabetes Endocrinol.2017515710.1016/S2213‑8587(16)30328‑X27863980
     [Google Scholar]
  12. NathanD.M. DavidsonM.B. DeFronzoR.A. Impaired fasting glucose and impaired glucose tolerance: Implications for care.Diabetes Care200730375375910.2337/dc07‑992017327355
     [Google Scholar]
  13. International Diabetes FederationIDF Diabetes Atlas.8th edBrussels, BelgiumInternational Diabetes Federation2017
     [Google Scholar]
  14. WildS. RoglicG. GreenA. SicreeR. KingH. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030.Diabetes Care20042751047105310.2337/diacare.27.5.104715111519
     [Google Scholar]
  15. LeeC.M. ColagiuriS. Diagnostic criteria and classification. In: Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment.Springer International Publishing2018232910.1007/978‑3‑319‑45015‑5_3
     [Google Scholar]
  16. American Diabetes AssociationClassification and diagnosis of diabetes.Sec. In standards of medical care in diabetes 2017.Diabetes Care2017401S11S24
     [Google Scholar]
  17. BullardK.M. SaydahS.H. ImperatoreG. Secular changes in U.S. Prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose: National health and nutrition examination surveys, 1999-2010.Diabetes Care20133682286229310.2337/dc12‑256323603918
     [Google Scholar]
  18. GersteinH.C. SantaguidaP. RainaP. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies.Diabetes Res. Clin. Pract.200778330531210.1016/j.diabres.2007.05.00417601626
     [Google Scholar]
  19. KowallB. RathmannW. HeierM. Categories of glucose tolerance and continuous glycemic measures and mortality.Eur. J. Epidemiol.201126863764510.1007/s10654‑011‑9609‑y21785986
     [Google Scholar]
  20. HermanW.H. PanQ. EdelsteinS.L. Impact of lifestyle and metformin interventions on the risk of progression to diabetes and regression to normal glucose regulation in overweight or obese people with impaired glucose regulation.Diabetes Care201740121668167710.2337/dc17‑111629021207
     [Google Scholar]
  21. KnowlerW.C. ConnorB.E. FowlerS.E. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.N. Engl. J. Med.2002346639340310.1056/NEJMoa01251211832527
     [Google Scholar]
  22. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation.Geneva: World Health Organization2006150
     [Google Scholar]
  23. WexlarD.J. NathanD.M. RubinowK. Management of persistence hyperglycemia in Diabetes Mellitus.2023Available from: https://www.uptodate.com/contents/management-of-persistenthyperglycemia-in-type-2-diabetes-mellitus
  24. JanghorbaniM. AminiM. Normal fasting plasma glucose and risk of prediabetes and type 2 diabetes: the Isfahan Diabetes Prevention Study.Rev. Diabet. Stud.20118449049810.1900/RDS.2011.8.49022580730
     [Google Scholar]
  25. KarveA. HaywardR.A. Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. adults.Diabetes Care201033112355235910.2337/dc09‑195720724649
     [Google Scholar]
  26. YipW. SequeiraI. PlankL. PoppittS. Prevalence of pre-diabetes across ethnicities: A review of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) for classification of Dysglycaemia.Nutrients2017911127310.3390/nu911127329165385
     [Google Scholar]
  27. BlumJ. AeschbacherS. SchoenT. Prevalence of prediabetes according to hemoglobin A1c versus fasting plasma glucose criteria in healthy adults.Acta Diabetol.201552363163210.1007/s00592‑014‑0659‑y25344149
     [Google Scholar]
  28. Treatment of type 2 diabetes mellitus in the older patient.2023Available from: https://www.uptodate.com/contents/treatment-of-type-2-diabetes-mellitus-in-the-older-patient
  29. PouyaS. IngaP. Global and regional diabetes prevalence estimates for 2019 and projections for 2023 and 2045: Results from International Diabetes and Federation Diabetes Atlas. Diabetes Resh.Clin. Pract.2019910
     [Google Scholar]
  30. FarmakiA.E. GarfieldV. EastwoodS.V. Type 2 diabetes risks and determinants in second-generation migrants and mixed ethnicity people of South Asian and African Caribbean descent in the UK.Diabetologia202265111312710.1007/s00125‑021‑05580‑734668055
     [Google Scholar]
  31. SunH. SaeediP. KarurangaS. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.Diabetes Res. Clin. Pract.202218310911910.1016/j.diabres.2021.10911934879977
     [Google Scholar]
  32. United Nations2018 Revision of world urbanization prospects.2018Available from: https://www.un.org/en/desa/2018-revision-world-urbanization-prospects
  33. RooneyM.R. FangM. OgurtsovaK. Global prevalence of prediabetes.Diabetes Care20234671388139410.2337/dc22‑237637196350
     [Google Scholar]
  34. PrashantM. SravyaL. VaitheeswaranK. Prevalence, awareness, treatment and control of diabetes.Frontiers202210
     [Google Scholar]
  35. What is prediabetes?2020Available from: https://www.healthline.com/health/type-2-diabetes/what-is-prediabetes#symptoms
  36. GarberA.J. Obesity and type 2 diabetes: Which patients are at risk?Diabetes Obes. Metab.201214539940810.1111/j.1463‑1326.2011.01536.x22074144
     [Google Scholar]
  37. BarbarrojaN. PedreraL.R. MayasM.D. The obese healthy paradox: Is inflammation the answer?Biochem. J.2010430114114910.1042/BJ2010028520522023
     [Google Scholar]
  38. WildS.H. ByrneC.D. Risk factors for diabetes and coronary heart disease.BMJ200633375761009101110.1136/bmj.39024.568738.4317095784
     [Google Scholar]
  39. AinsworthB. HaskellW.L. LeonA.S. Compendium of physical activities: Classification of energy costs of human physical activities.Med. Sci. Sports Exerc.1993251718010.1249/00005768‑199301000‑000118292105
     [Google Scholar]
  40. WilmotE.G. EdwardsonC.L. AchanaF.A. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: Systematic review and meta-analysis.Diabetologia201255112895290510.1007/s00125‑012‑2677‑z22890825
     [Google Scholar]
  41. Centers for Disease Control and PreventionNational diabetes statistics report.2017Available from: https://www.cdc.gov/diabetes/data/statistics-report/index.html
  42. AliA. Health Survey for England Cardiovascular Disease and Risk Factors in Adults.London, UKNational Centre for Social Research2008
     [Google Scholar]
  43. SuastikaK. DwipayanaP. SaraswatiR.I.M. Relationship between age and metabolic disorders in the population of Bali.JCGG201122475210.1016/j.jcgg.2011.03.001
     [Google Scholar]
  44. Nam HanC. JosesK. JeanC.M. Diabetes Atlas.8th edDiabetes by Region2017
     [Google Scholar]
  45. Kautzky-WillerA. LeutnerM. HarreiterJ. Sex differences in type 2 diabetes.Diabetologia2023666986100210.1007/s00125‑023‑05891‑x36897358
     [Google Scholar]
  46. GarawiF. DevriesK. ThorogoodN. UauyR. Global differences between women and men in the prevalence of obesity: Is there an association with gender inequality?Eur. J. Clin. Nutr.201468101101110610.1038/ejcn.2014.8624918120
     [Google Scholar]
  47. WillerK.A. HarreiterJ. PaciniG. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus.Endocr. Rev.201637327831610.1210/er.2015‑113727159875
     [Google Scholar]
  48. AdamZ.R. SaraD.N. Sex- biased gene regulation varies across human populations as a result of adaptive evolution.BioRxiv2023
     [Google Scholar]
  49. GaboryA. AttigL. JunienC. Developmental programming and epigenetics.Am. J. Clin. Nutr.201194S6S1943S195210.3945/ajcn.110.00092722049164
     [Google Scholar]
  50. PetrieJ.R. GuzikT.J. TouyzR.M. Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms.Can. J. Cardiol.201834557558410.1016/j.cjca.2017.12.00529459239
     [Google Scholar]
  51. YonasA. YitayehB. Hypertension and its associated factors among type 2 diabtes mellitus patients at debre tabor general hospital. north-west ethiopia.Dovepress2020201316211631
     [Google Scholar]
  52. FowlerM.J. Microvascular and macrovascular complications of diabetes.Clin. Diabetes2008262778210.2337/diaclin.26.2.77
     [Google Scholar]
  53. CheungB.M.Y. LiC. Diabetes and hypertension: Is there a common metabolic pathway?Curr. Atheroscler. Rep.201214216016610.1007/s11883‑012‑0227‑222281657
     [Google Scholar]
  54. CheungB.M.Y. The hypertension-diabetes continuum.J. Cardiovasc. Pharmacol.201055433333910.1097/FJC.0b013e3181d2643020422737
     [Google Scholar]
  55. CarlssonS. MidthjellK. GrillV. Smoking is associated with an increased risk of type 2 diabetes but a decreased risk of autoimmune dia-betes in adults: An 11-year follow-up of incidence of diabetes in the Nord-Trøndelag study.Diabetologia200447111953195610.1007/s00125‑004‑1554‑915558231
     [Google Scholar]
  56. WilliC. BodenmannP. GhaliW.A. FarisP.D. CornuzJ. Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis.JAMA2007298222654266410.1001/jama.298.22.265418073361
     [Google Scholar]
  57. MadsbadS. McNairP. ChristensenM.S. Influence of smoking on insulin requirement and metbolic status in diabetes mellitus.Diabetes Care198031414310.2337/diacare.3.1.416996967
     [Google Scholar]
  58. ChenZ. LiuX. KennyP.J. Central and peripheral actions of nicotine that influence blood glucose homeostasis and the development of diabetes.Pharmacol. Res.202319410686010.1016/j.phrs.2023.10686037482325
     [Google Scholar]
  59. EpifanoL. Di VincenzoA. FanelliC. Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus.Eur. J. Clin. Pharmacol.199243325726310.1007/BF023330191425888
     [Google Scholar]
  60. FratiA.C. IniestraF. ArizaC.R. Acute effect of cigarette smoking on glucose tolerance and other cardiovascular risk factors.Diabetes Care199619211211810.2337/diacare.19.2.1128718429
     [Google Scholar]
  61. MillsJ.D. GrantP.J. Insulin resistance, haemostatic factors and cardiovascular risk.Br. J. Diabetes Vasc. Dis.200221192610.1177/14746514020020011301
     [Google Scholar]
  62. MonsalveF.A. PyarasaniR.D. LopezD.F. CarrascoM.R. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.Mediators Inflamm.2013201311810.1155/2013/54962723781121
     [Google Scholar]
  63. MaddatuJ. BaucumA.E. MolinaE.C. Smoking and the risk of type 2 diabetes.Transl. Res.201718410110710.1016/j.trsl.2017.02.00428336465
     [Google Scholar]
  64. TuovinenE.L. SaarniS.E. MännistöS. Smoking status and abdominal obesity among normal- And overweight/obese adults: Population-based FINRISK study.Prev. Med. Rep.2016432433010.1016/j.pmedr.2016.07.00327486563
     [Google Scholar]
  65. KaoW.H.L. PuddeyI.B. BolandL.L. WatsonR.L. BrancatiF.L. Alcohol consumption and the risk of type 2 diabetes mellitus: Atherosclerosis risk in communities study.Am. J. Epidemiol.2001154874875710.1093/aje/154.8.74811590088
     [Google Scholar]
  66. KnottC. BellS. BrittonA. Alcohol consumption and the risk of type 2 diabetes: A systematic review and dose-response meta-analysis of more than 1.9 million individuals from 38 observational studies.Diabetes Care20153891804181210.2337/dc15‑071026294775
     [Google Scholar]
  67. BuczkowskaO.E. MachnicaŁ. Obesity and overweight in children and adolescents as a risk factor of glucose homeostasis disturbances and their complications.Clin. Diabetes2011125180187
     [Google Scholar]
  68. ZhaoJ. Association between daily alcohol intake and risk of all-cause mortality.JAMA Netw. Open202363e236185
     [Google Scholar]
  69. RichelsenB. TonstadS. RossnerS. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: A 3-year randomized, placebo-controlled study.Diabetes Care20073012732
     [Google Scholar]
  70. Van GaalL.F. ScheenA.J. RissanenA.M. RössnerS. HanotinC. ZieglerO. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: Two year results from the RIO-Europe Study.Eur. Heart J.200829141761177110.1093/eurheartj/ehn07618417461
     [Google Scholar]
  71. NilssonP.M. Is weight loss beneficial for reduction of morbidity and mortality? What is the controversy about?Diabetes Care200831S2S278S28310.2337/dc08‑s26818227497
     [Google Scholar]
  72. BuchwaldH. EstokR. FahrbachK. Weight and type 2 diabetes after bariatric surgery: Systematic review and meta-analysis.Am. J. Med.20091223248256.e510.1016/j.amjmed.2008.09.04119272486
     [Google Scholar]
  73. ColquittJ.L. PicotJ. LovemanE. CleggA.J. Surgery for obesity.Cochrane Database Syst. Rev.20092CD00364119370590
     [Google Scholar]
  74. GarberA.J. Hypertension and lipid management in prediabetic states.J. Clin. Hypertens.201113427027410.1111/j.1751‑7176.2011.00451.x21466625
     [Google Scholar]
  75. Diabetes Prevention Program (DPP) Research GroupThe Diabetes Prevention Program (DPP): Description of lifestyle intervention.Diabetes Care200225122165217110.2337/diacare.25.12.216512453955
     [Google Scholar]
  76. ChwalbaA. BuczkowskaO.E. Metabolic syndrome is the problem in young diabetics?Fam Med Sci20143427
     [Google Scholar]
/content/journals/cdr/10.2174/0115733998285294240307052909
Loading
Conceptual Overview of Prevalence of Prediabetes
Curr. Diabetes Rev. 21, E030424228558 (2025); https://doi.org/10.2174/0115733998285294240307052909
/content/journals/cdr/10.2174/0115733998285294240307052909
/content/journals/cdr/10.2174/0115733998285294240307052909
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): American diabetes association; dysglycemia; glycated haemoglobin levels; impaired fasting glucose; impaired glucose tolerance; Prediabetes; prevalence; world health organization

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test